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Background: The expression of 5-hydroxymethylcytosine (5-hmC) and isocitrate dehydrogenase 2 (IDH2) is
frequently downregulated in numerous cancers. 5-hmC and IDH2 expression in hepatocellular carcinoma (HCC)
has yet to be determined.
Methods: The immunohistochemical expression of 5-hmC and IDH2 were analyzed in tissue microarrays containing
samples from 646 patients who had undergone hepatectomy for histologically proven HCC. The prognostic value
of 5-hmC and IDH2 were evaluated by Cox regression and Kaplan-Meier analyses.
Results: We discovered that low 5-hmC and IDH2 expression was associated with malignant behaviors. Low 5-hmC
or IDH2 expression alone and combined 5-hmC and IDH2 expression were associated with lower overall survival
(OS) rates and higher cumulative recurrence rates. Multivariate analysis indicated that 5-hmC or IDH2 and 5-hmC/IDH2
were independent prognostic indicators for OS and time to recurrence (TTR), which was confirmed in an independent
validation cohort.
Conclusions: 5-hmC and IDH2 correlate with less aggressive tumor behavior in HCC. When 5-hmC and IDH2 are
considered together, they serve as a prognostic marker in patients with surgically resected HCCs.
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PrognosisBackground
Liver cancer is the fifth most common cancer in men
and the seventh most common in women, and hepato-
cellular carcinoma (HCC) is diagnosed in more than half
a million of these liver cancer patients worldwide each
year [1]. Despite intensive research, the prognosis of
HCC remains poor, with an overall 5-year survival rate
of approximately 26% in the United States [2]. There is a
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survival outcomes.
In the current cancer research landscape, epigenetics
is a promising and expanding field [3-6]. DNA methyla-
tion, an important pattern of epigenetics, was historically
believed to be a relatively stable chromatin modification,
but the detection of the presence of 5-hmC facilitated a
breakthrough in the field of epigenetic research [7,8]. 5-
hmC, also known as the “sixth base”, was identified as
an oxidant product of 5-methylcytosine (5mC) via the
ten-eleven translocation (TET) family, which consists of
TET1, −2, and −3. 5-hmC is abundant in embryonic
stem (ES) cells and adult neural cells [8-10]. Currently,
the biological prevalence of 5-hmC in cancer remains
elusive. Lian et al. reported that the loss of 5-hmC wasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and prognostic efficiency [11]. 5-hmC levels were high
in low-grade tumors and decreased in malignant glioma
[12]. Regarding gastroenteric tumors, 5-hmC was de-
creased in colorectal cancer (CRC) and gastric cancer [13].
In liver cancer, 5-hmC was also decreased compared with
the surrounding normal tissue [14-16].
Isocitrate dehydrogenases (IDHs) catalyze the oxidative
decarboxylation of isocitrate, which converts isocitrate to
α-ketoglutarate (KG). The IDHs include IDH1 in the cyto-
plasm and IDH2 in the mitochondria, which catalyze an
identical reaction [17] (Additional file 1: Figure S1). IDH1
and IDH2 mutations widely occur in gliomas and acute
myeloid leukemia [18-21], leading to the production of 2-
hydroxyglutarate (2-HG), which inhibits multiple α-KG-
dependent dioxygenases, including the TET family of
5-mC hydroxylases (which results in decreased 5-hmC)
[22]. Lian et al. found that IDH2 was significantly down-
regulated in melanoma [11]. However, 5-hmC and IDH2
expression in HCC have yet to be characterized in a large
series of tumors with documented clinical, pathological,
and molecular information.
In this study, we sought to determine the clinical rele-
vance of 5-hmC and IDH2 protein expression in a large
series of surgically resected HCCs using two cohorts. We
studied the association between these two proteins and
tumor history, as well as the patients’ clinical-pathologic
features, including age, sex, stage, overall survival (OS),
and time to recurrence (TTR). We found that combined
5-hmC and IDH2 protein expression was an independent
prognostic factor for HCC patients after surgery.
Materials and methods
Patients and specimens
Archival specimens were obtained from two cohorts of
consecutive patients with HCC who underwent curative
resection at the Liver Cancer Institute, Zhongshan Hos-
pital, Fudan University, between 2006 and 2007. The pa-
tient cohort inclusion and exclusion criteria included (a)
accurate pathologic diagnosis of HCC, (b) complete clin-
icopathologic and follow-up data, (c) no anticancer treat-
ment prior to curative liver resection, and (d) complete
formalin-fixed, paraffin-embedded tissues. The histo-
pathological diagnosis was determined according to the
World Health Organization criteria. Tumor differenti-
ation was graded using the Edmondson grading system
[23]. Tumor staging was based on the 6th edition of the
tumor-node-metastasis (TNM) classification of the Inter-
national Union Against Cancer. Most patients (82.4%) had
a hepatitis B virus background, and only two patients had
hepatitis C virus. Almost all patients (316 of 318 for the
training cohort and 325 of 328 for the validation cohort)
were in the Child-Pugh A classification. The clinicopatho-
logic characteristics of the two cohorts are summarized inAdditional file 2: Table S1. Ethical approval was obtained
from the Zhongshan Hospital Research Ethics Committee,
and written informed consent was obtained from each
patient.
Follow-up and postoperative treatment
The follow-up data were summarized at the end of De-
cember 2011, with a median observation time of
52.2 months. The follow-up procedures were described
in our previous study [23,24]. Postsurgical patient sur-
veillance was undertaken as previously described [23,25].
OS was defined as the interval between the dates of sur-
gery and death. TTR was defined as the interval between
the dates of surgery and the dates of any diagnosed re-
currence (intrahepatic recurrence and extrahepatic me-
tastasis). For surviving patients, the data were censored
at the date of death or last follow-up.
Tissue microarray and immunohistochemistry
Tissue microarray (TMA) was conducted as previously de-
scribed [26-28]. Briefly, all samples from the HCC patients
were reviewed by three histopathologists and representative
areas located away from necrotic and hemorrhagic materials
were premarked in the paraffin blocks. Two core biopsies
(1 mm in diameter) were taken from each representative
tumor tissue and peritumoral tissue to construct the TMA
slides. Consecutive sections measuring 4 μm were placed
on 3-aminopropyltriethoxysilane-coated slides (Shanghai
Biochip Co Ltd, Shanghai, People’s Republic of China).
Immunohistochemistry of the paraffin sections was per-
formed using a two-step protocol (Novolink Polymer
Detection System, Novocastra) according to the manu-
facturer’s instructions. Briefly, paraffin-embedded sections
were deparaffinized and then rehydrated; after heat-induced
antigen retrieval, endogenous peroxidases were blocked for
5 min using 0.3% H2O2, washed twice, and then incubated
for 5 min in Serum-Free Protein Block (Novocastra),
followed by incubation for 60 min in purified rabbit anti-
human 5-hmC and rabbit anti-human IDH2 with DaVinci
Green antibody diluent (Biocare Medical). The sections
were incubated in a 3, 3-diaminobenzidine solution, coun-
terstained with hematoxylin, dehydrated in ethanol, cleared
in xylene, and coverslipped. Negative controls were treated
in all assays (with the omission of primary antibodies). The
sections were visualized using microscopic observation.
Evaluation of the immunohistochemical findings
IHC staining was assessed by two independent pathologists
without knowledge of the clinical and pathologic features
of the cases. A negative control array was concurrently
undertaken showing < 1% nuclear staining in all specimens.
All specimens were evaluated according to the 0–4 grading
criteria (based on the percentage of 5-hmC-positive cells)
and 0–3 grading criteria (based on the staining intensity)
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cell count × the score of intensity. The median 5-hmC score
was used as a cut-off in subsequent analyses. For IDH2
quantification, photographs of three representative fields
were captured under high-power magnification (200×)
using Leica Qwin Plus v3 software; identical settings were
used for each photograph. The 5-hmC and IDH2 density
were counted using Image-Pro Plus v6.2 software (Media
Cybernetics Inc., Bethesda, MD). The integrated optical
density of the area positively stained for IDH2 in each
photograph was calculated, and its ratio to the total area of
each photograph was considered to be the IDH2 density.
The median IDH2 density was used as a cut-off in subse-
quent analyses.
Statistical analysis
The data were analyzed with SPSS 19.0 software, as pre-
viously described [23]. A P value <0.05 was considered
statistically significant.
Results
Immunohistochemical features in TMA
Using hematoxylin and eosin staining, the cancer cells
were found to be relatively homogenous within a tumor
(excluding necrotic, hemorrhagic, and fibrotic compo-
nents). Representative cases of immunohistochemical
staining are shown in Figure 1. We observed 5-hmC
staining primarily on the nuclei of the tumor cells and
hepatocytes; IDH2 staining was observed primarily in
the cytoplasm of the HCC cells. Most of the stromal
cells were negatively stained, although sporadic positive
staining of these cells was observed.
Correlations of 5-hmC and IDH2 expression with clinico-
pathologic characteristics
The correlations of 5-hmC and IDH2 expression with
the clinicopathologic characteristics are shown in Table 1
and Additional file 2: Table S2. In the training cohort, 5-
hmC expression correlated with sex (P =0.007) and AFPFigure 1 Expression of 5-hmC and IDH2 in HCC samples (training coh
of 5-hmC (brown in the nucleus of HCC cells) and IDH2 (brown in the cyto(P <0.001). IDH2 expression only correlated with tumor
differentiation (P =0.017) (Table 1). In the validation co-
hort, 5-hmC expression correlated with sex (P =0.003),
age (P =0.034), AFP (P <0.001), tumor number (P =0.02),
and TNM stage (P =0.009). IDH2 expression correlated
with HBsAg (P =0.015), AFP (P <0.001), and tumor differ-
entiation (P =0.015) (Additional file 2: Table S2). Other
clinical characteristics were not directly related to the ex-
pression of 5-hmC or IDH2.
Association between combined 5-hmC and IDH2
expression and outcome in the training cohort
By the last follow-up in the training cohort (November
2011), 47.2% (150/318) of the patients had suffered a re-
currence and 36.5% (116/318) had died. The 1-, 3-, and
5-year OS rates in the cohort were 83.6%, 67.6%, and
63.5% and the cumulative recurrence rates were 32.7%,
46.9%, and 52.8%, respectively. Additionally, we found that
the 1-, 3-, and 5-year survival rates of the 5-hmC High
patients were significantly higher than those of the
5-hmC Low group (87.4% vs. 79.9%, 77.4% vs. 57.9%, and
73.0% vs. 54.1%, respectively) (Figure 2a). Similarly, the
5-hmC Low patients had a poorer prognosis at 1, 3, and
5 years, with higher cumulative recurrence rates than
the 5-hmC High patients (40.3% vs. 25.2%, 56.6% vs.
37.1%, and 61.6% vs. 44.0%, respectively) (Figure 2b). We
also discovered that the 1-, 3-, and 5-year survival rates of
the IDH2 High patients were significantly higher than those
of the IDH2 Low group (93.7% vs. 73.6%, 76.7% vs. 58.5%,
and 71.7% vs. 55.3%, respectively) (Figure 2a). Similarly, the
IDH2 Low patients had a poorer prognosis at 1-, 3-, and
5- years, with higher cumulative recurrence rates than the
IDH2 High patients (40.3% vs. 25.2%, 52.2% vs. 41.5%, and
58.5% vs. 47.2%, respectively) (Figure 2b). Furthermore,
we evaluated the combined effect of 5-hmC and IDH2 ex-
pression. We found that the 1-, 3-, and 5-year OS rates in
the 5-hmC Low/IDH2 Low patients were 64.6%, 43.1%, and
43.1%, respectively, which were significantly lower than
those in the 5-hmC High/IDH2 High patients (98.5%, 89.2%,ort, n = 318). Representative HCC tumor samples show the expression
plasm of HCC cells). Scale bar, 200×, 200 μm.
Table 1 Summary of the correlations of 5-hmC and IDH2 protein expression with clinicopathological features in the
training cohort (N = 318)
Clinicopathological indexes No. of patients No. of patients
5-hmC Low 5-hmC High P† IDH2 Low IDH2 High P†
Sex Female 18 36 0.007 28 26 0.765
Male 141 123 131 133
Age(year) ≤50 55 65 0.247 60 60 1.000
>50 104 94 99 99
HBsAg Negative 30 26 0.556 28 28 1.000
Positive 129 133 131 131
HCV Negative 158 158 1.000 157 159 0.156
Positive 1 1 2 0
AFP ≤20 83 37 <0.001 58 62 0.644
>20 76 122 101 97
γ-GT(U/L) ≤54 87 81 0.500 78 90 0.178
>54 72 78 81 69
Liver cirrhosis No 32 26 0.384 23 35 0.081
Yes 127 133 136 124
Tumor number Single 131 134 0.652 134 131 0.652
Multiple 28 25 25 28
Tumor size(cm) ≤5 97 108 0.197 99 106 0.412
>5 62 51 60 53
Tumor encapsulation Complete 94 88 0.496 93 89 0.650
None 65 71 66 70
Microvascular invasion Absent 113 107 0.466 106 114 0.331
Present 46 52 53 45
Tumor differentiation I + II 129 115 0.063 113 131 0.017
III + IV 30 44 46 28
TNM stage I 98 93 0.567 93 98 0.567
II + III 61 66 66 61
Abbreviations: HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; γ-GT, γ-glutamyl transferase; TNM, tumor-node-metastasis.
†A P-value < 0.05 was considered statistically significant. P-values were calculated using the Pearson chi-square test. Boldface type indicates significant values.
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rence rates in the 5-hmC Low/IDH2 Low patients were
52.3%, 63.1% and 66.2%, respectively, which were signi-
ficantly higher than those in the 5-hmC High/IDH2 High
patients (15.4%, 26.2% and 30.8%, respectively) (Figure 2b).
Univariate analysis revealed that 5-hmC (P <0.001 and
P = 0.001), IDH2 (P <0.001 and P = 0.006), and 5-hmC/
IDH2 combined (P <0.001 and P <0.001) were associated
with OS and TTR. γ-GT, tumor number, tumor size,
microvascular invasion, and TNM stage were predictors
of OS and TTR. Moreover, AFP was only associated with
OS, and liver cirrhosis was only associated with TTR
(Table 2).
The individual clinicopathological features that pre-
sented significance in the univariate analysis were adopted
as covariates in a multivariate Cox proportional hazards
model for further analysis. 5-hmC and IDH2 wereprognostic indicators of OS (P <0.001 and P <0.001) and
TTR (P <0.001 and P =0.001). When 5-hmC was com-
bined with IDH2, we found that 5-hmC/IDH2 was also an
independent prognostic indicator of both OS (P <0.001)
and TTR (P <0.001) (Figure 2 and Table 2).
Validation analysis of the better outcome of patients in
the validation cohort with 5-hmC High/IDH2 High
expression
To validate our findings of better outcomes in patients
with 5-hmC High/IDH2 High expression, we studied a val-
idation cohort that included 328 surgically resected
HCC tumors. Briefly, we found that the 1- and 3-year
OS rates in the 5-hmC Low/IDH2 Low patients were
66.3% and 46.3%, respectively, which were significantly
lower than those in the 5-hmC High/IDH2 High patients
(97.0% and 79.0%, respectively) (Figure 3a). The cumulative
Figure 2 5-hmC and IDH2 expression and prognostic value in HCC tissue (training cohort, N = 318). Kaplan-Meier curves depiciting OS (a)
and TTR (b) for 5-hmC expression, IDH2 expression, and combined 5-hmC/IDH2 expression. I, 5-hmC High/IDH2 High; II, 5-hmC Low/IDH2 High;
III, 5-hmC High/IDH2 Low; IV, 5-hmC Low/IDH2 Low.
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52.5% and 71.3%, respectively, which were significantly
higher than those in the 5-hmC High/IDH2 High patients
(19.0% and 36.0%, respectively) (Figure 3b).
Univariate analysis revealed that 5-hmC (P <0.001 and
P <0.001), IDH2 (P =0.001 and P <0.001), and 5-hmC/
IDH2 combined (P <0.001 and P <0.001) were associated
with OS and TTR. In a multivariate Cox proportional haz-
ards model, 5-hmC and IDH2 were prognostic indicators
of OS (P =0.005 and P =0.005) and TTR (P =0.008 and
P =0.02). When 5-hmC and IDH2 were combined, we
found that 5-hmC/IDH2 was also an independent pro-
gnostic indicator of both OS (P =0.007) and TTR
(P =0.009) (Additional file 2: Table S3).
Discussion
To date, the available data on 5-hmC and IDH2 in HCC
have been limited. In this study, we investigated theclinical relevance of 5-hmC and IDH2 protein expres-
sion in two large cohorts (n = 646) of surgically resected
HCCs with 318 cases and 328 cases, respectively.
We determined that high 5-hmC expression was sig-
nificantly associated with favorable features in HCC pa-
tients. This finding may be substantiated by the fact that
aggressive histopathological characteristics, including a
high AFP level was significantly more frequent in pa-
tients with low 5-hmC expression than in those with
high expression in training cohort. And a high AFP level,
more tumor number, and an advanced TNM staging of
HCC were more detected in those patients with low 5-
hmC expression in validation cohort. This indicated that
5-hmC may be a powerful prognostic indicator in HCC.
5-hmC, an oxidation product of 5mC via the TET family
(which consists of TET1, −2, and −3), is abundant in ES
cells and adult neural cells [8]. The relationship between
5-hmC and tumors is emerging through a number of
Table 2 Summary of univariate and multivariate analyses of 5-hmC and IDH2 protein expression associated with
survival and recurrence in the training cohort (N = 318)
Factor OS TTR
Multivariate Multivariate
Univariate P Hazard ratio 95% CI P† Univariate P Hazard ratio 95% CI P†
Sex (female vs. male) 0.959 NA 0.083 NA
Age, years (≤50 vs. >50) 0.772 NA 0.597 NA
HBsAg (negative vs. positive) 0.983 NA 0.491 NA
AFP, ng/ml (≤20 vs. >20) 0.041 1.893 1.257–2.852 0.002 0.230 NA
γ-GT, U/L (≤54 vs. >54) 0.006 1.619 1.118–2.343 0.011 0.003 1.547 1.138–2.102 0.005
Liver cirrhosis (no vs. yes) 0.077 NA 0.009 1.824 1.135–2.930 0.013
Tumor number (single vs. multiple) 0.003 NS 0.002 1.651 1.135–2.402 0.009
Tumor size, cm (≤5 vs. >5) 0.009 NS 0.041 NS
Tumor encapsulation (complete vs. none) 0.261 NA 0.166 NA
Microvascular invasion (no vs. yes) 0.003 NS 0.001 1.775 1.287–2.448 <0.001
Tumor differentiation (I-II vs. III-IV) 0.138 NA 0.053 NA
TNM stage (I vs. II III) <0.001 2.048 1.412–2.971 <0.001 <0.001 1.649 1.134–2.397 0.009
5-hmC (low vs. high) <0.001 0.316 0.211–0.472 <0.001 0.001 0.462 0.335–0.636 <0.001
IDH2 (low vs. high) <0.001 0.405 0.275–0.594 <0.001 0.006 0.591 0.432–0.810 0.001
Combination of 5-hmC and IDH2 <0.001 <0.001 <0.001 <0.001
I versus II 0.002 3.987 1.890–8.413 <0.001 0.001 2.651 1.576–4.461 <0.001
I versus III 0.002 3.359 1.607–7.025 0.001 0.003 2.098 1.247–3.530 0.005
I versus IV <0.001 8.908 4.215–18.825 <0.001 <0.001 3.891 2.270–6.671 <0.001
Abbreviations: OS, overall survival; TTR time to recurrence; AFP, α-fetoprotein; γ-GT, γ-glutamyl transferase; TNM, tumor-node-metastasis; CI, confidence interval;
NA, not adopted; NS, not significant.
†Cox proportional hazards regression. Boldface type indicates significant values.
I, 5-hmC High/IDH2 High; II, 5-hmC Low/IDH2 High; III, 5-hmC High/IDH2 Low; IV, 5-hmC Low/IDH2 Low.
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sion was decreased in liver cancer compared with the
surrounding normal tissue [14,15]. Although previous
studies have addressed 5-hmC protein expression using
IHC in archived HCC tissues, the number of cases is
limited and lacks further validation. Our study repre-
sents the largest analysis of 5-hmC protein expression in
HCC.
We also detected significant correlations between low
IDH2 expression and HBsAg background, a high level of
AFP, and low-grade tumor differentiation. IDH2, an IDH
(which convert isocitrate to α-KG), is frequently mutated
in cancer, particularly in secondary glioblastoma [30], cy-
togenetically normal acute myeloid leukemia (AML)
[31], cartilaginous tumors [32], and intrahepatic cholan-
giocarcinoma [33]. The pathophysiological function of
the R-enantiomer of 2-hydroxylglutarate (R-2-HG) is the
driving force of IDH1/2 mutation-induced tumorigenesis
[22]. In melanoma, IDH2 is frequently downregulated,
and the overexpression of IDH2 in a zebrafish melanoma
model has been shown to increase the level of 5-hmC,
resulting in prolonged tumor-free survival [11]. In our
group, the preliminary experimental results indicated a
tumor suppressor role for IDH2 in HCC (unpublisheddata); however, the expression of mutated IDH2, the
mechanisms of IDH2 mutation, and the precise role of
IDH2 in HCC remain under investigation.
One of most notable findings of our study was that
the expression of 5-hmC or IDH2 alone, as well as the
expression of the combination of 5-hmC and IDH2,
was significantly correlated with OS and TTR in two
cohorts. Thus, we made a direct comparison of prog-
nosis between four subgroups (5-hmC High/IDH2 High,
5-hmC Low/IDH2 High, 5-hmC High/IDH2 Low, and
5-hmC Low/IDH2 Low) in the training cohort. As expected,
patients with 5-hmC High/IDH2 High expression had a
significantly better OS and TTR than the patients in
the other 3 groups in both univariate and multivariate
analyses. These interesting observations were confirmed
in a second cohort (validation cohort) that exhibited
clinical-pathological features similar to the first cohort
(training cohort).
In addition to genetic alterations, epigenetic alterations
were also considered to participate in carcinogenesis
[34]. It is also plausible that the two mechanisms can co-
exist and interact, giving birth to the observed hot-spot
tumor heterogeneity [35,36]. The mechanisms of this
interaction are currently the chief investigational pursuit
Figure 3 5-hmC and IDH2 expression and prognostic value in HCC tissue (validation cohort, N = 328). Kaplan-Meier curves depiciting OS
(a) and TTR (b) for 5-hmC expression, IDH2 expression, and combined 5-hmC/IDH2 expression. I, 5-hmC High/IDH2 High; II, 5-hmC Low/IDH2 High; III,
5-hmC High/IDH2 Low; IV, 5-hmC Low/IDH2 Low.
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nostic value of 5-hmC and IDH2 in HCC; further inves-
tigations are in progress.
The major limitation of the present work was its retro-
spective nature. Moreover, it is noteworthy that most
HCC patients in China have a hepatitis B virus-positive
background, which differs from studies in Japan, Europe,
and the United States.
To the best of our knowledge, this is the first paper
demonstrating the implications of 5-hmC and IDH2 in
HCC. Our findings indicate that a high expression of 5-
hmC and IDH2 predicts comparably less aggressive
tumor behavior. Importantly, 5-hmC expression (par-
ticularly when combined with IDH2 expression) enables
us to more accurately predict the true prognosis of HCC
patients. Moreover, given the proposed epigenetic nature
of 5-hmC and IDH2, the therapeutic manipulation of 5-
hmC and IDH2 will assist in guiding clinical strategies.Conclusions
In summary, 5-hmC and IDH2 correlate with less ag-
gressive tumor behavior in HCC. Low 5-hmC or IDH2
expression alone and combined 5-hmC and IDH2 ex-
pression were associated with lower OS rates and higher
cumulative recurrence rates. When 5-hmC and IDH2
are considered together, they serve as a prognostic
marker in patients with surgically resected HCCs.
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